A retrospective series of long-term survivors of metastatic breast cancer in complete remission

Oncology

Volumn 68, Issue 1, 2005, Pages 48-51

  Amoroso, Vito ^a   Valcamonico, Francesca ^a   Simoncini, Edda ^a   Ardighieri, Laura ^a   Grisanti, Salvatore ^a   Vassalli, Lucia ^a   Marpicati, Patrizia ^a   Lucini, Laura ^a   Ferrari, Vittorio D ^a   Rangoni, Giovanni ^a   Marini, Giovanni ^a  

^a Azienda Spedali Civili   (Italy)

Author keywords

Breast cancer; Chemotherapy; Metastatic breast cancer; Multidisciplinary treatments; Survival

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; DOCETAXEL; MEGESTROL ACETATE; TAMOXIFEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE DURATION; ENDOCRINE DISEASE; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HORMONAL THERAPY; HUMAN; METASTASIS; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR LOCALIZATION; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVOR; TIME;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SURVIVORS; TIME FACTORS;

EID: 20944433105     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000084819     Document Type: Article

References (14)

1. Singletary SE, Allred C, Ashley P, et al: Revision of the American Joint Committee on cancer staging system for breast cancer. J Clin Oncol 2002;20:3628-3636.
2. Hortobagyi GN: Treatment of breast cancer. N Engl J Med 1998;339:974-984.
3. Swenerton KD, Legha SS, Smith T, et al: Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 1979;39:1552-1562.
4. Greenberg PA, Hortobagyi GN, Smith TL, et al: Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:2197-2205.
5. Tomiak E, Piccart M, Mignolet F, et al: Characterisation of complete responders to combination chemotherapy for advanced breast cancer: A retrospective EORTC Breast Group study. Eur J Cancer 1996;32A:1876-1887.
6. Pedrazzini A, Cavalli F, Brunner KW, et al: Complete remission following endocrine or combined cytotoxic and hormonal treatment in advanced breast cancer. Oncology 1987;44:51-59.
7. Marini G, Simoncini E, Zaniboni A, et al: 5-Fluorouracil and high-dose folinic acid as salvage treatment of advanced breast cancer: An update. Oncology 1987;44:336-340.
8. Zaniboni A, Simoncini E, Marpicati P, et al: Cyclofosfamide, epirubicin, high-dose folinic acid and 5-fluorouracil (super-FEC) as first-line chemotherapy for advanced breast cancer: Preliminary results. Eur J Cancer Clin Oncol 1989;25:1151-1155.
9. Lamont EB, Hayreh D, Pickett KE, et al: Is patient travel distance associated with survival on phase II clinical trials in oncology? J Natl Cancer Inst 2003;95:1370-1375.
10. Horthobagyi GN: Can we cure limited metastatic breast cancer? J Clin Oncol 2001;20:620-623.
11. Bruzzi P: Objective response to treatment as a potential surrogate marker of survival in breast cancer. Ann NY Acad Sci 2002;963:144-147.
12. Valagussa P, Tancini G, Bonadonna G: Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy. Cancer 1986;58:1411-1417.
13. Castiglione-Gertsch M, Tattersall M, Hacking A, et al: Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. The International Breast Cancer Study Group. Eur J Cancer 1997;33:2321-2325.
14. Houston SJ, Richards MA, Bentley AE, et al: The influence of adjuvant chemotherapy on outcome after relapse for patients with breast cancer. Eur J Cancer 1993;29A:1513-1518.